Shen Lian Biomedical details strategic shifts, capital use, and reduced net loss

Shanghai Shen Lian Biomedical Corporation (SSE:688098) will hold its second extraordinary general meeting on September 25, 2025, to approve major governance changes, including the abolition of the Supervisory Board, and revisions to its Articles of Association. This decision follows a review and approval by the Fourth Board of Directors at its fourth meeting on August 29, 2025, in line with new company law. The board’s audit committee will assume the responsibilities previously held by the Supervisory Board.

In its half-year report for January-June 2025, Shen Lian Biomedical reported a net loss attributable to shareholders of CNY -12,869,700.94, a significant reduction from the CNY -34,507,973.32 loss in the same period last year. Total revenue for the period was CNY 121,725,138.28.

The company’s raised capital of CNY 400,175,000.00, net of issuance expenses, has been managed through dedicated bank accounts. As of June 30, 2025, the company reported using CNY 335,293,800.00 of its raised funds, with the remaining balance used to permanently replenish working capital after the completion of the "Animal Inactivated Vaccine Project."

Shen Lian Biomedical's strategic focus includes expanding into innovative human medicine, with a CNY 60,000,000.00 investment in Yangzhou Shizhiyuan Biomedical Technology Co., Ltd. for drug development, representing a 20.48% stake. Raised funds are allocated across various projects, with CNY 238,470,600.00 used for the "Suspension Culture Foot-and-Mouth Disease Inactivated Vaccine Project" and CNY 96,823,200.00 for the "Animal Inactivated Vaccine Project."